Ads
related to: what are antibodies
Search results
Wuthering Waves: When the Forest is No Longer Dim puzzles
VG247· 14 hours agoThroughout all of the diverse landscapes in Wuthering Waves, few are as mysterious as the Banyan...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 5 days agoMerus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today ...
GSK builds case for return of multiple myeloma drug Blenrep
BioPharma Dive via Yahoo Finance· 6 days agoStudy results showed the antibody-drug conjugate helped stave off disease progression better than a...
... 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in...
Char-Koosta News· 6 days agoMore updated data from the Phase 1 study including in non-small cell...
FDLI’s Top Cases 2024 Featuring Partner Andrew Wasson | JD Supra
JD Supra· 1 day agoPartner Andrew Wasson contributed a chapter to the Food & Drug Law Institute’s annual publication identifying the top food and drug cases of the year. Amgen v. Sanofi is undeniably and thoroughly ...
Arrivent Biopharma enters into cancer drug development collaboration valued at up to $615M -...
The Business Journals· 3 days agoArriVent, based in Newtown Square, will team with Jiangsu Alphamab Biopharmaceutical to discover and...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 20 hours agoNEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 17 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate...
Benzinga· 4 days agoFibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175,
